# Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

> **NCT07144254** · PHASE1 · RECRUITING · sponsor: **Emory University** · enrollment: 24 (estimated)

## Conditions studied

- Osteosarcoma Recurrent
- Osteosarcoma in Children
- Relapsed Osteosarcoma
- Refractory Osteosarcoma

## Interventions

- **DRUG:** Tegavivint
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT07144254
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-22
- **Primary completion:** 2028-05
- **Final completion:** 2028-05
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07144254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07144254, "Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07144254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*